drugset / Trial / NCT06253117
Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.
Phase 2
Recruiting
60 enrolled
University of Alabama at Birmingham
Congressionally Directed Medical Research Programs · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This clinical will evaluate the safety, tolerability and early efficacy of pirenidone in patients with recurrent acute pancreatitis.
Timeline
- Start
- 2024-06-27
- Primary completion
- 2028-09-01
- Completion
- 2028-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pirfenidone | Small molecule | 801 mg | Oral |